1 Outlook 2021 is inclusive of anticipated COVID-19 effects and excl. special items. Special items include costs related to the FME25 program and effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. The growth rates are based on the results 2020 excl. the impairment charge of goodwill and trade names in the Latin America segment of €195 M. For a reconciliation of figures excl. special items, please refer to the table at the end of the press release.
2 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA.
3 Results 2020: excl. impairment charge.